Market Place
Sourcing Support
Coherus Biosciences Sells Udenyca Franchise to Intas Pharma
04 Dec 2024 //
PRESS RELEASE
Enforcement Report - Week of November 6, 2024
06 Nov 2024 //
FDA
Enforcement Report - Week of October 23, 2024
23 Oct 2024 //
FDA
Accord Healthcare Receives Positive CHMP Opinion for Imuldosa
19 Oct 2024 //
PR NEWSWIRE
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY
21 Sep 2024 //
PR NEWSWIRE
Accord BioPharma’s HERCESSI secures FDA approval
30 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
Intas Pharmaceuticals is on FDA Import Alert List
10 Apr 2024 //
FDA
Intas inks agreement for treating autoimmune diseases in 150+ countries
20 Dec 2023 //
BIOSPECTRUM ASIA
USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant
10 Dec 2023 //
ECONOMIC TIMES
FDA put Intas plant on import alert, warning letter shows
29 Nov 2023 //
FIERCE PHARMA
Intas Pharmaceuticals Limited Receives FDA Warning Letter
28 Nov 2023 //
FDA
Intas Pharmaceuticals Limited on FDA Import Alert List
14 Nov 2023 //
FDA
Henlius Deepens Collaboration with Intas to bring Serplulimab to Europe & India
27 Oct 2023 //
PR NEWSWIRE
USFDA issues warning letter to Intas Pharma for Sanand plant
06 Aug 2023 //
ECONOMIC TIMES
Intas Pharmaceuticals Receives FDA Warning Letter
01 Aug 2023 //
FDA
FDA slams Intas, Ipca over manufacturing shortfalls at 3 plants
07 Jul 2023 //
FIERCE PHARMA
FDA Issues From 483 to Intas Pharmaceuticals
05 Jul 2023 //
FDA
Intas Pharmaceuticals Limited on FDA Import Alert List
06 Jun 2023 //
FDA
Intas Pharmaceuticals Limited on Health Canada Inspection List
05 Jun 2023 //
HEALTH CANADA
India`s Intas gets more bad news from FDA with import alert
05 Jun 2023 //
FIERCE PHARMA
Enforcement Report - Week of May 31, 2023
31 May 2023 //
FDA
Enforcement Report - Week of May 10, 2023
10 May 2023 //
FDA
Bankruptcy court approves Intas-Shamrock plan for Unimark Remedies
18 Apr 2023 //
ECONOMIC TIMES
Enforcement Report - Week of March 8, 2023
08 Mar 2023 //
FDA
Enforcement Report - Week of January 25, 2023
25 Jan 2023 //
FDA
Intas` Gujarat, India facility is in the FDA`s crosshairs
20 Jan 2023 //
FIERCE PHARMA
Intas under FDA scrutiny over `cascade of failure` in oversight of GMP documents
19 Jan 2023 //
ENDPTS
FDA Issues Form 483 to Intas Pharmaceuticals Ltd.
18 Jan 2023 //
FDA
FDA Issues Form 483 to Intas Pharma
12 Jan 2023 //
FDA
Intas Pharma — USFDA issues Form-483 with 11 observations for Gujarat unit
11 Jan 2023 //
CNBCTV18
Intas Pharma to commercialise Syna Therapeutics’ biosimilar drug LB-0702
02 Nov 2022 //
PHARMABIZ
CCI clears Abu Dhabi Investment Authority`s minority stake buy in Intas Pharma
10 Oct 2022 //
ECONOMIC TIMES
Intas & Dr Reddy`s in race with PEs to buy US` Athenex
05 Aug 2022 //
ECONOMIC TIMES
Prestige Biopharma and Intas Partner to Commercialize Bevacizumab Biosimilar
26 Jul 2022 //
BUSINESSWIRE
Abu Dhabi Sovereign Fund to buy into Intas Pharma
26 Apr 2022 //
ECONOMIC TIMES
Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration
19 Apr 2022 //
BUSINESSWIRE
Intas, Axantia ink agreement to commercialise Ranibizumab in Middle East
05 Apr 2022 //
HEALTH ET
Intas Pharma signs supply agreement for Ranibizumab biosimilar in Middle East
05 Apr 2022 //
BIOSPECTRUMASIA
Accord Bio, Foresee Pharma Partner to Launch CAMCEVI Injection Emulsion
04 Apr 2022 //
PRNEWSWIRE
NPPA expert panel fixes price for Intas Pharma’s incremental Ig solution
08 Mar 2022 //
PHARMABIZ
Intas Pharms` Generic Sitagliptin Receives Approval in the U.S.
02 Mar 2022 //
FDA
J&J back in court over new generic threat from Intas
19 Feb 2022 //
ENDPTS
Indian firm Intas Pharma makes breakthrough in antifungal therapy domain
13 Oct 2021 //
BIOSPECTRUMASIA
Intas enters license agreement with Meiji and Dong commercialize DMB-3115
22 Jul 2021 //
PRNEWSWIRE
Intas enters into agreement with Meiji and Dong-A ST to commercialise DMB-3115
22 Jul 2021 //
EXPRESS PHARMA
Research Finds Babylon Digital-first Model Of Primary Care Lower Significantly
22 Jul 2021 //
PRNEWSWIRE
Intas enters into agreement with Meiji and Dong-A ST to commercialise DMB-3115
22 Jul 2021 //
EXPRESS PHARMA
Research Finds Babylon Digital-first Model Of Primary Care Lower Significantly
22 Jul 2021 //
PRNEWSWIRE
Intas enters license agreement with Meiji and Dong commercialize DMB-3115
22 Jul 2021 //
PRNEWSWIRE
Foresee Enters Exclusive License Agreement with Intas Pharmaceuticals
04 Mar 2021 //
PRNEWSWIRE
Alteogen Enters Into an Exclusive License Agreement With Intas
07 Jan 2021 //
BUSINESSWIRE
Covid-19 fight: Indian companies join race to develop blood products
25 Sep 2020 //
BUSINESS STANDARD
Naari completes acquisition of ANDAs from Intas Pharmaceuticals
11 Jun 2020 //
BIOSPECTRUMASIA
Intas Pharma to donate 2 million hydroxychloroquine tablets for WHO
30 Mar 2020 //
THEHINDUBUSINESSLINE
Advisory issued against retinal disease drug
15 Feb 2019 //
ECONOMIC TIMES
CCI probe finds unfair practices by three drug companies
20 Sep 2018 //
ECONOMIC TIMES
Gilenya (Fingolimod): Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al
18 Jul 2018 //
PATENT LITIGATION
Senispar® (cinacalcet hydrochloride): Amgen Inc. v. Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.
29 Jun 2018 //
PATENT LITIGATION
Chrys Capital to buy 10% in Mankind for $350 M
02 Apr 2018 //
BIOSPECTRUM
